Erasca, Inc. (ERAS) experienced a significant intraday surge of 8.78% on Thursday, reflecting strong investor interest in the biotechnology stock.

The sharp price increase followed the company's publication of a corporate presentation detailing its RAS/MAPK cancer drug pipeline. Erasca highlighted positive early clinical data from its AURORAS-1 Phase 1/1b trial for ERAS-0015, a Pan-RAS molecular glue, with responses first observed at the 8 mg once daily dose. As of January 7, 2026, the trial reported ongoing responses including 2 confirmed partial responses and 1 unconfirmed partial response.

Investors were also encouraged by the company's robust financial position, which includes $342 million in cash, cash equivalents, and marketable securities as of December 31, 2025, and an oversubscribed equity financing that closed in January 2026. The company anticipates its cash runway will extend into the second half of 2028, providing substantial funding for its clinical development programs.